The SCAN Project was developed in 2010 from fieldwork in assessing the needs of the pharmaceutical industry as a tool capable of integrating all the company areas involved in the complex Market Access process.
Access to the pharmaceutical market In Italy is problematical due to the presence of various factors: the dominance of objectives linked to cost control, the extensive use of comparative analysis and therapeutic equivalence, and the fragmentation of pharmaceutical policies at regional level.
All this has led to a situation that is characterized by prices that are often lower than the EU average, significant delays in accessing the market, and scarce penetration for certain diseases.
OBJECTIVES AND OUTPUTS
In a context as complex as ours, an integrated Market Access approach is indispensable. The SCAN Project (Turnkey System for New Drug Market Access) was developed in response to this need.
Funded by the Lombardia Region’s 2010 FIMSER Call for Tenders with the objective of supporting the industry in managing adequate value proposition for access to the market through the integration of related activities: Pricing and Reimbursement, Outcome Research, Health Economics, Public Affairs, and Marketing.
The SCAN system permits the value-based definition of a new drug’s price after validation by an interdisciplinary panel composed of pharmacologists, health economists, and clinical experts, and therefore the development of Budget Impact and Market Forecast analyses at regional level, in this way enabling the measurement of regional performances for specific political, institutional, and economic contexts.
- Prof. Pier Luigi Canonico, Director of the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale;
- Prof. Claudio Jommi, Associate Professor at the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale; Scientific Director Drugs Observatory, Cergas, Università Bocconi.